Bevacizumab in Glioblastoma — Still Much to Learn
Mené sur 458 patients atteints d'un glioblastome supratentoriel récemment diagnostiqué, cet essai de phase III évalue, du point de vue de la survie sans progression, de la survie globale et des événements indésirables, l'intérêt d'ajouter le bévacizumab à une radiothérapie en combinaison avec le témozolomide...
Glioblastoma, which remains one of the most lethal tumors, is associated with a median survival of only approximately 15 months, despite aggressive combination therapy. Interest in therapeutic targeting of the florid angiogenesis characteristic of glioblastoma led to several phase 2 trials of bevacizumab, a humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF), in patients with recurrent glioblastoma.1–3 These early trials showed dramatic and unprecedented responses on magnetic resonance imaging (MRI) (and, occasionally, clinical responses) among patients with a recurrent tumor for which no effective treatment existed, thereby leading to approval of bevacizumab by the Food and Drug . . .
New England Journal of Medicine , éditorial, 2013